'Approximately 20 percent of participants were 65 years and over, and approximately 60 percent had comorbidities associated with an increased risk for progression of severe COVID-19, such as diabetes, severe obesity or cardiac disease'This is a very good vaccine
AstraZeneca-Oxford University COVID-19 vaccine shows 79% efficacy in US Phase-3 trials
The DSMB found no increased risk of thrombosis or events characterised by thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for CVST found no events in this trial, AstraZeneca said.www.moneycontrol.com
100% effectiveness against severe disease with that cohort is encouraging.
Still, all of these vaccines are going to live and die by their ability to combat variants and we already know that AstraZeneca is struggling against the Saffer strain.